Pura Vida Investments’s Immunic IMUX Stock Holding History

Pura Vida Investments’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-68,329	Closed	-$4.38M	–	239
2022 Q1	$7.72M	Buy	+68,329	New	+$7.91M	0.25%	96

Other funds holding IMUX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Pura Vida Investments's IMUX Position: Q2 2022 in Review

Pura Vida Investments sold out of Immunic (IMUX) in Q2 2022, closing a stake of 68,329 shares — an estimated $4.38M sold.

Pura Vida Investments first reported a position in IMUX in Q1 2022 and held it in 1 quarter. The position peaked at $7.72M in Q1 2022. 72 funds tracked by Wall St. Rank hold IMUX as of Q2 2022.

Pura Vida Investments reported no remaining Immunic position as of Q2 2022 after selling out during the quarter.
Pura Vida Investments sold 68,329 Immunic shares in Q2 2022, an estimated $4.38M.
Pura Vida Investments first reported a position in Immunic in Q1 2022 and held it in 1 quarter.
Pura Vida Investments's Immunic position peaked at $7.72M in Q1 2022.
72 funds tracked by Wall St. Rank held Immunic as of Q2 2022.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.